From 00bbf7d191a77549f311458899555d0ab8586d2f Mon Sep 17 00:00:00 2001 From: Davide Garolini Date: Fri, 13 Oct 2023 21:36:56 +0200 Subject: [PATCH] Update snapshots after formatters changes in wrapping (#65) Co-authored-by: ayogasekaram --- DESCRIPTION | 8 +- tests/testthat/_snaps/listing_egl01.md | 100 ++++++++++---------- tests/testthat/_snaps/listing_lbl01.md | 94 +++++++++--------- tests/testthat/_snaps/listing_lbl01_rls.md | 100 ++++++++++---------- tests/testthat/_snaps/listing_lbl02a.md | 100 ++++++++++---------- tests/testthat/_snaps/listing_lbl02a_rls.md | 100 ++++++++++---------- tests/testthat/_snaps/listing_lbl02b.md | 100 ++++++++++---------- tests/testthat/_snaps/listing_oncl01.md | 6 +- tests/testthat/_snaps/listing_vsl01.md | 100 ++++++++++---------- tests/testthat/_snaps/pagination_table.md | 12 +-- tests/testthat/_snaps/table_coxt01.md | 92 +++++++++--------- tests/testthat/_snaps/table_ratet01.md | 44 ++++----- tests/testthat/test-pagination_listing.R | 6 +- tests/testthat/test-table_pkct01.R | 2 +- 14 files changed, 434 insertions(+), 430 deletions(-) diff --git a/DESCRIPTION b/DESCRIPTION index 41b1dae0..ea903cba 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -21,11 +21,11 @@ License: Apache License 2.0 | file LICENSE URL: https://github.com/insightsengineering/scda.test/ BugReports: https://github.com/insightsengineering/scda.test/issues Depends: - formatters (>= 0.5.1.9005), + formatters (>= 0.5.3.9002), R (>= 3.6), - rlistings (>= 0.2.3.9003), - rtables (>= 0.6.2.9003), - tern (>= 0.8.5.9013) + rlistings (>= 0.2.5.9002), + rtables (>= 0.6.4.9003), + tern (>= 0.9.1.9005) Imports: scda (>= 0.1.6.9012), scda.2022 (>= 0.1.5.9002) diff --git a/tests/testthat/_snaps/listing_egl01.md b/tests/testthat/_snaps/listing_egl01.md index 0bb7b881..5dd31e51 100644 --- a/tests/testthat/_snaps/listing_egl01.md +++ b/tests/testthat/_snaps/listing_egl01.md @@ -10,56 +10,56 @@ Study (beats/min); Heart Rate (msec); QT Duration (msec); RR Duration Center/Subject ID Age/Sex/Race Treatment Visit Day Range:(40-100) Change from BL Range:(200-500) Change from BL Range:(600-1500) Change from BL ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— - BRA-1/105 38/M/BLACK OR AFRICAN AMERICAN A: Drug X BASELINE 149 66.94 NA 441.78 NA 896.59 NA - WEEK 1 DAY 8 314 63.18 -3.76 365.68 -76.10 1376.26 479.67 - WEEK 2 DAY 15 398 57.57 -9.37 355.48 -86.29 799.57 -97.02 - WEEK 3 DAY 22 470 73.36 6.42 352.45 -89.33 1015.00 118.41 - WEEK 4 DAY 29 528 53.72 -13.22 388.42 -53.36 1189.29 292.70 - WEEK 5 DAY 36 535 58.25 -8.69 291.77 -150.01 936.09 39.50 - BRA-1/134 47/M/WHITE A: Drug X BASELINE 227 46.99 NA 385.29 NA 835.17 NA - WEEK 1 DAY 8 255 48.38 1.39 453.74 68.46 901.86 66.68 - WEEK 2 DAY 15 269 35.40/L -11.59 413.54 28.26 892.01 56.84 - WEEK 3 DAY 22 357 60.50 13.51 394.23 8.95 490.18/L -344.99 - WEEK 4 DAY 29 436 82.28 35.29 398.29 13.00 757.96 -77.21 - WEEK 5 DAY 36 440 38.89/L -8.10 339.38 -45.91 880.26 45.08 - BRA-1/141 35/F/WHITE C: Combination BASELINE 52 92.83 NA 302.14 NA 1436.04 NA - WEEK 1 DAY 8 189 67.20 -25.63 197.02/L -105.11 988.48 -447.56 - WEEK 2 DAY 15 262 71.22 -21.60 255.81 -46.33 1494.56 58.52 - WEEK 3 DAY 22 386 71.39 -21.44 245.22 -56.92 1193.28 -242.76 - WEEK 4 DAY 29 425 69.49 -23.34 369.92 67.78 976.32 -459.72 - WEEK 5 DAY 36 730 81.26 -11.56 199.68/L -102.45 779.76 -656.28 - BRA-1/236 32/M/BLACK OR AFRICAN AMERICAN B: Placebo BASELINE 275 88.84 NA 418.61 NA 1608.46/H NA - WEEK 1 DAY 8 431 34.23/L -54.61 449.83 31.21 1148.53 -459.93 - WEEK 2 DAY 15 781 68.53 -20.31 451.56 32.94 735.17 -873.29 - WEEK 3 DAY 22 794 61.68 -27.16 271.38 -147.24 1511.04/H -97.42 - WEEK 4 DAY 29 988 72.77 -16.08 504.72/H 86.10 831.54 -776.92 - WEEK 5 DAY 36 1034 77.03 -11.81 373.15 -45.46 817.91 -790.55 - BRA-1/265 25/M/WHITE C: Combination BASELINE 536 68.05 NA 432.79 NA 979.52 NA - WEEK 1 DAY 8 582 89.87 21.81 490.91 58.11 1189.90 210.38 - WEEK 2 DAY 15 671 95.29 27.23 257.48 -175.32 1261.08 281.56 - WEEK 3 DAY 22 699 71.03 2.98 310.41 -122.38 1014.56 35.04 - WEEK 4 DAY 29 704 83.32 15.27 420.27 -12.52 918.71 -60.80 - WEEK 5 DAY 36 723 87.36 19.31 235.62 -197.17 1171.56 192.04 - BRA-1/42 36/M/BLACK OR AFRICAN AMERICAN A: Drug X BASELINE 477 56.19 NA 190.94/L NA 1276.65 NA - WEEK 1 DAY 8 534 85.24 29.05 483.71 292.77 735.11 -541.54 - WEEK 2 DAY 15 550 55.53 -0.66 386.60 195.66 1092.71 -183.94 - WEEK 3 DAY 22 569 65.37 9.18 311.08 120.14 1227.15 -49.50 - WEEK 4 DAY 29 608 65.13 8.93 329.78 138.83 250.18/L -1026.47 - WEEK 5 DAY 36 675 49.03 -7.16 470.67 279.73 1321.21 44.56 - BRA-1/65 25/F/BLACK OR AFRICAN AMERICAN B: Placebo BASELINE 230 82.82 NA 205.48 NA 722.06 NA - WEEK 1 DAY 8 269 24.66/L -58.16 519.98/H 314.50 897.36 175.30 - WEEK 2 DAY 15 413 70.60 -12.22 418.58 213.11 1137.03 414.97 - WEEK 3 DAY 22 639 62.17 -20.65 332.44 126.96 1238.78 516.72 - WEEK 4 DAY 29 762 80.62 -2.20 430.06 224.59 1053.92 331.86 - WEEK 5 DAY 36 868 64.10 -18.72 430.28 224.80 683.17 -38.89 - BRA-1/93 34/F/ASIAN A: Drug X BASELINE 73 72.12 NA 306.64 NA 1324.80 NA - WEEK 1 DAY 8 207 66.88 -5.24 190.50/L -116.14 1495.37 170.58 - WEEK 2 DAY 15 359 83.93 11.81 321.37 14.74 1141.92 -182.88 - WEEK 3 DAY 22 373 87.12 15.00 350.94 44.30 1342.87 18.08 - WEEK 4 DAY 29 422 35.23/L -36.89 279.28 -27.36 1055.72 -269.08 - WEEK 5 DAY 36 426 49.56 -22.56 300.84 -5.80 785.27 -539.53 - BRA-11/171 40/F/ASIAN C: Combination BASELINE 49 76.56 NA 320.56 NA 735.92 NA - WEEK 1 DAY 8 211 33.10/L -43.45 406.68 86.12 905.99 170.06 + BRA-1/105 38/M/BLACK OR AFRICAN AMERICAN A: Drug X BASELINE 149 66.94 NA 441.78 NA 896.59 NA + WEEK 1 DAY 8 314 63.18 -3.76 365.68 -76.10 1376.26 479.67 + WEEK 2 DAY 15 398 57.57 -9.37 355.48 -86.29 799.57 -97.02 + WEEK 3 DAY 22 470 73.36 6.42 352.45 -89.33 1015.00 118.41 + WEEK 4 DAY 29 528 53.72 -13.22 388.42 -53.36 1189.29 292.70 + WEEK 5 DAY 36 535 58.25 -8.69 291.77 -150.01 936.09 39.50 + BRA-1/134 47/M/WHITE A: Drug X BASELINE 227 46.99 NA 385.29 NA 835.17 NA + WEEK 1 DAY 8 255 48.38 1.39 453.74 68.46 901.86 66.68 + WEEK 2 DAY 15 269 35.40/L -11.59 413.54 28.26 892.01 56.84 + WEEK 3 DAY 22 357 60.50 13.51 394.23 8.95 490.18/L -344.99 + WEEK 4 DAY 29 436 82.28 35.29 398.29 13.00 757.96 -77.21 + WEEK 5 DAY 36 440 38.89/L -8.10 339.38 -45.91 880.26 45.08 + BRA-1/141 35/F/WHITE C: Combination BASELINE 52 92.83 NA 302.14 NA 1436.04 NA + WEEK 1 DAY 8 189 67.20 -25.63 197.02/L -105.11 988.48 -447.56 + WEEK 2 DAY 15 262 71.22 -21.60 255.81 -46.33 1494.56 58.52 + WEEK 3 DAY 22 386 71.39 -21.44 245.22 -56.92 1193.28 -242.76 + WEEK 4 DAY 29 425 69.49 -23.34 369.92 67.78 976.32 -459.72 + WEEK 5 DAY 36 730 81.26 -11.56 199.68/L -102.45 779.76 -656.28 + BRA-1/236 32/M/BLACK OR AFRICAN AMERICAN B: Placebo BASELINE 275 88.84 NA 418.61 NA 1608.46/H NA + WEEK 1 DAY 8 431 34.23/L -54.61 449.83 31.21 1148.53 -459.93 + WEEK 2 DAY 15 781 68.53 -20.31 451.56 32.94 735.17 -873.29 + WEEK 3 DAY 22 794 61.68 -27.16 271.38 -147.24 1511.04/H -97.42 + WEEK 4 DAY 29 988 72.77 -16.08 504.72/H 86.10 831.54 -776.92 + WEEK 5 DAY 36 1034 77.03 -11.81 373.15 -45.46 817.91 -790.55 + BRA-1/265 25/M/WHITE C: Combination BASELINE 536 68.05 NA 432.79 NA 979.52 NA + WEEK 1 DAY 8 582 89.87 21.81 490.91 58.11 1189.90 210.38 + WEEK 2 DAY 15 671 95.29 27.23 257.48 -175.32 1261.08 281.56 + WEEK 3 DAY 22 699 71.03 2.98 310.41 -122.38 1014.56 35.04 + WEEK 4 DAY 29 704 83.32 15.27 420.27 -12.52 918.71 -60.80 + WEEK 5 DAY 36 723 87.36 19.31 235.62 -197.17 1171.56 192.04 + BRA-1/42 36/M/BLACK OR AFRICAN AMERICAN A: Drug X BASELINE 477 56.19 NA 190.94/L NA 1276.65 NA + WEEK 1 DAY 8 534 85.24 29.05 483.71 292.77 735.11 -541.54 + WEEK 2 DAY 15 550 55.53 -0.66 386.60 195.66 1092.71 -183.94 + WEEK 3 DAY 22 569 65.37 9.18 311.08 120.14 1227.15 -49.50 + WEEK 4 DAY 29 608 65.13 8.93 329.78 138.83 250.18/L -1026.47 + WEEK 5 DAY 36 675 49.03 -7.16 470.67 279.73 1321.21 44.56 + BRA-1/65 25/F/BLACK OR AFRICAN AMERICAN B: Placebo BASELINE 230 82.82 NA 205.48 NA 722.06 NA + WEEK 1 DAY 8 269 24.66/L -58.16 519.98/H 314.50 897.36 175.30 + WEEK 2 DAY 15 413 70.60 -12.22 418.58 213.11 1137.03 414.97 + WEEK 3 DAY 22 639 62.17 -20.65 332.44 126.96 1238.78 516.72 + WEEK 4 DAY 29 762 80.62 -2.20 430.06 224.59 1053.92 331.86 + WEEK 5 DAY 36 868 64.10 -18.72 430.28 224.80 683.17 -38.89 + BRA-1/93 34/F/ASIAN A: Drug X BASELINE 73 72.12 NA 306.64 NA 1324.80 NA + WEEK 1 DAY 8 207 66.88 -5.24 190.50/L -116.14 1495.37 170.58 + WEEK 2 DAY 15 359 83.93 11.81 321.37 14.74 1141.92 -182.88 + WEEK 3 DAY 22 373 87.12 15.00 350.94 44.30 1342.87 18.08 + WEEK 4 DAY 29 422 35.23/L -36.89 279.28 -27.36 1055.72 -269.08 + WEEK 5 DAY 36 426 49.56 -22.56 300.84 -5.80 785.27 -539.53 + BRA-11/171 40/F/ASIAN C: Combination BASELINE 49 76.56 NA 320.56 NA 735.92 NA + WEEK 1 DAY 8 211 33.10/L -43.45 406.68 86.12 905.99 170.06 ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are diff --git a/tests/testthat/_snaps/listing_lbl01.md b/tests/testthat/_snaps/listing_lbl01.md index 8139be4b..3ef12a91 100644 --- a/tests/testthat/_snaps/listing_lbl01.md +++ b/tests/testthat/_snaps/listing_lbl01.md @@ -10,56 +10,56 @@ Study Last Dose of ALT CRP IGA Center/Patient ID Treatment Day Study Drug (U/L / NCI CTCAE grade) (mg/L / NCI CTCAE grade) (g/L / NCI CTCAE grade) ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— - BRA-1/id-105 A: Drug X 80 NA 4.30 / L4 9.09 2.84 - 149 69 24.70 9.15 2.93 - 314 165 24.87 10.89 / H2 2.66 - 398 84 3.67 / L3 8.14 2.86 - 470 72 18.55 10.59 / H3 2.88 - 528 58 7.73 10.09 / H3 2.93 - 535 7 23.51 9.20 2.88 - BRA-1/id-134 A: Drug X 225 NA 7.37 10.46 / H1 2.86 - 227 2 16.42 7.43 / L1 2.76 - 255 28 11.16 9.41 2.75 - 269 14 15.89 10.02 / H4 2.84 - 357 88 24.35 8.01 2.86 - 436 79 16.03 8.51 2.98 - 440 4 17.21 7.63 / L3 2.78 - BRA-1/id-141 C: Combination 4 NA 11.32 9.21 2.84 - 52 48 25.77 10.00 / H2 2.69 - 189 137 32.73 9.08 2.85 - 262 73 34.69 8.81 2.81 - 386 124 8.58 8.81 2.81 - 425 39 19.58 8.79 2.87 + BRA-1/id-105 A: Drug X 80 NA 4.30 / L4 9.09 2.84 + 149 69 24.70 9.15 2.93 + 314 165 24.87 10.89 / H2 2.66 + 398 84 3.67 / L3 8.14 2.86 + 470 72 18.55 10.59 / H3 2.88 + 528 58 7.73 10.09 / H3 2.93 + 535 7 23.51 9.20 2.88 + BRA-1/id-134 A: Drug X 225 NA 7.37 10.46 / H1 2.86 + 227 2 16.42 7.43 / L1 2.76 + 255 28 11.16 9.41 2.75 + 269 14 15.89 10.02 / H4 2.84 + 357 88 24.35 8.01 2.86 + 436 79 16.03 8.51 2.98 + 440 4 17.21 7.63 / L3 2.78 + BRA-1/id-141 C: Combination 4 NA 11.32 9.21 2.84 + 52 48 25.77 10.00 / H2 2.69 + 189 137 32.73 9.08 2.85 + 262 73 34.69 8.81 2.81 + 386 124 8.58 8.81 2.81 + 425 39 19.58 8.79 2.87 730 305 23.28 8.92 3.01 / H3 BRA-1/id-236 B: Placebo 12 NA 17.43 10.54 / H2 3.05 / H1 - 275 263 29.52 9.50 2.85 - 431 156 22.29 9.11 2.88 - 781 350 10.06 9.10 2.82 - 794 13 28.16 10.99 / H1 2.80 - 988 194 3.63 / L1 9.33 2.71 - 1034 46 21.10 10.38 / H1 2.99 - BRA-1/id-265 C: Combination 41 NA 32.32 10.13 / H1 2.90 - 536 495 20.44 8.52 2.96 - 582 46 10.80 7.44 / L4 2.94 - 671 89 7.03 7.23 / L2 2.94 - 699 28 8.75 9.24 2.85 - 704 5 32.09 9.47 2.69 - 723 19 17.79 9.94 2.89 - BRA-1/id-42 A: Drug X 176 NA 16.56 8.88 2.75 - 477 301 16.49 8.11 2.95 - 534 57 18.71 8.78 2.95 - 550 16 11.44 9.53 2.99 + 275 263 29.52 9.50 2.85 + 431 156 22.29 9.11 2.88 + 781 350 10.06 9.10 2.82 + 794 13 28.16 10.99 / H1 2.80 + 988 194 3.63 / L1 9.33 2.71 + 1034 46 21.10 10.38 / H1 2.99 + BRA-1/id-265 C: Combination 41 NA 32.32 10.13 / H1 2.90 + 536 495 20.44 8.52 2.96 + 582 46 10.80 7.44 / L4 2.94 + 671 89 7.03 7.23 / L2 2.94 + 699 28 8.75 9.24 2.85 + 704 5 32.09 9.47 2.69 + 723 19 17.79 9.94 2.89 + BRA-1/id-42 A: Drug X 176 NA 16.56 8.88 2.75 + 477 301 16.49 8.11 2.95 + 534 57 18.71 8.78 2.95 + 550 16 11.44 9.53 2.99 569 19 21.66 10.32 / H2 3.00 / H1 - 608 39 24.61 7.95 / L2 2.78 - 675 67 23.49 8.46 2.83 - BRA-1/id-65 B: Placebo 218 NA 0.05 / L1 7.13 / L2 2.83 - 230 12 24.33 8.04 2.75 - 269 39 8.18 9.05 2.91 - 413 144 14.12 8.05 2.78 - 639 226 24.86 7.09 / L3 2.93 - 762 123 19.38 8.49 2.78 - 868 106 31.52 8.49 2.96 - BRA-1/id-93 A: Drug X 19 NA 14.69 9.15 2.79 + 608 39 24.61 7.95 / L2 2.78 + 675 67 23.49 8.46 2.83 + BRA-1/id-65 B: Placebo 218 NA 0.05 / L1 7.13 / L2 2.83 + 230 12 24.33 8.04 2.75 + 269 39 8.18 9.05 2.91 + 413 144 14.12 8.05 2.78 + 639 226 24.86 7.09 / L3 2.93 + 762 123 19.38 8.49 2.78 + 868 106 31.52 8.49 2.96 + BRA-1/id-93 A: Drug X 19 NA 14.69 9.15 2.79 ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— NCI CTCAE grade is displayed as abnormal high (H) or low (L) followed by the grade. diff --git a/tests/testthat/_snaps/listing_lbl01_rls.md b/tests/testthat/_snaps/listing_lbl01_rls.md index 2de49555..d4543ca7 100644 --- a/tests/testthat/_snaps/listing_lbl01_rls.md +++ b/tests/testthat/_snaps/listing_lbl01_rls.md @@ -10,56 +10,56 @@ Study Last Dose of ALT CRP IGA Center/Patient ID Treatment Day Study Drug (U/L) (mg/L) (g/L) —————————————————————————————————————————————————————————————————————————————————————————————— - BRA-1/id-105 A: Drug X 80 NA 4.30 / L 9.09 2.84 - 149 69 24.70 9.15 2.93 - 314 165 24.87 10.89 / H 2.66 - 398 84 3.67 / L 8.14 2.86 - 470 72 18.55 10.59 / H 2.88 - 528 58 7.73 10.09 / H 2.93 - 535 7 23.51 9.20 2.88 - BRA-1/id-134 A: Drug X 225 NA 7.37 10.46 / H 2.86 - 227 2 16.42 7.43 / L 2.76 - 255 28 11.16 9.41 2.75 - 269 14 15.89 10.02 / H 2.84 - 357 88 24.35 8.01 2.86 - 436 79 16.03 8.51 2.98 - 440 4 17.21 7.63 / L 2.78 - BRA-1/id-141 C: Combination 4 NA 11.32 9.21 2.84 - 52 48 25.77 10.00 / H 2.69 - 189 137 32.73 9.08 2.85 - 262 73 34.69 8.81 2.81 - 386 124 8.58 8.81 2.81 - 425 39 19.58 8.79 2.87 - 730 305 23.28 8.92 3.01 / H - BRA-1/id-236 B: Placebo 12 NA 17.43 10.54 / H 3.05 / H - 275 263 29.52 9.50 2.85 - 431 156 22.29 9.11 2.88 - 781 350 10.06 9.10 2.82 - 794 13 28.16 10.99 / H 2.80 - 988 194 3.63 / L 9.33 2.71 - 1034 46 21.10 10.38 / H 2.99 - BRA-1/id-265 C: Combination 41 NA 32.32 10.13 / H 2.90 - 536 495 20.44 8.52 2.96 - 582 46 10.80 7.44 / L 2.94 - 671 89 7.03 7.23 / L 2.94 - 699 28 8.75 9.24 2.85 - 704 5 32.09 9.47 2.69 - 723 19 17.79 9.94 2.89 - BRA-1/id-42 A: Drug X 176 NA 16.56 8.88 2.75 - 477 301 16.49 8.11 2.95 - 534 57 18.71 8.78 2.95 - 550 16 11.44 9.53 2.99 - 569 19 21.66 10.32 / H 3.00 / H - 608 39 24.61 7.95 / L 2.78 - 675 67 23.49 8.46 2.83 - BRA-1/id-65 B: Placebo 218 NA 0.05 / LL 7.13 / L 2.83 - 230 12 24.33 8.04 2.75 - 269 39 8.18 9.05 2.91 - 413 144 14.12 8.05 2.78 - 639 226 24.86 7.09 / L 2.93 - 762 123 19.38 8.49 2.78 - 868 106 31.52 8.49 2.96 - BRA-1/id-93 A: Drug X 19 NA 14.69 9.15 2.79 + BRA-1/id-105 A: Drug X 80 NA 4.30 / L 9.09 2.84 + 149 69 24.70 9.15 2.93 + 314 165 24.87 10.89 / H 2.66 + 398 84 3.67 / L 8.14 2.86 + 470 72 18.55 10.59 / H 2.88 + 528 58 7.73 10.09 / H 2.93 + 535 7 23.51 9.20 2.88 + BRA-1/id-134 A: Drug X 225 NA 7.37 10.46 / H 2.86 + 227 2 16.42 7.43 / L 2.76 + 255 28 11.16 9.41 2.75 + 269 14 15.89 10.02 / H 2.84 + 357 88 24.35 8.01 2.86 + 436 79 16.03 8.51 2.98 + 440 4 17.21 7.63 / L 2.78 + BRA-1/id-141 C: Combination 4 NA 11.32 9.21 2.84 + 52 48 25.77 10.00 / H 2.69 + 189 137 32.73 9.08 2.85 + 262 73 34.69 8.81 2.81 + 386 124 8.58 8.81 2.81 + 425 39 19.58 8.79 2.87 + 730 305 23.28 8.92 3.01 / H + BRA-1/id-236 B: Placebo 12 NA 17.43 10.54 / H 3.05 / H + 275 263 29.52 9.50 2.85 + 431 156 22.29 9.11 2.88 + 781 350 10.06 9.10 2.82 + 794 13 28.16 10.99 / H 2.80 + 988 194 3.63 / L 9.33 2.71 + 1034 46 21.10 10.38 / H 2.99 + BRA-1/id-265 C: Combination 41 NA 32.32 10.13 / H 2.90 + 536 495 20.44 8.52 2.96 + 582 46 10.80 7.44 / L 2.94 + 671 89 7.03 7.23 / L 2.94 + 699 28 8.75 9.24 2.85 + 704 5 32.09 9.47 2.69 + 723 19 17.79 9.94 2.89 + BRA-1/id-42 A: Drug X 176 NA 16.56 8.88 2.75 + 477 301 16.49 8.11 2.95 + 534 57 18.71 8.78 2.95 + 550 16 11.44 9.53 2.99 + 569 19 21.66 10.32 / H 3.00 / H + 608 39 24.61 7.95 / L 2.78 + 675 67 23.49 8.46 2.83 + BRA-1/id-65 B: Placebo 218 NA 0.05 / LL 7.13 / L 2.83 + 230 12 24.33 8.04 2.75 + 269 39 8.18 9.05 2.91 + 413 144 14.12 8.05 2.78 + 639 226 24.86 7.09 / L 2.93 + 762 123 19.38 8.49 2.78 + 868 106 31.52 8.49 2.96 + BRA-1/id-93 A: Drug X 19 NA 14.69 9.15 2.79 —————————————————————————————————————————————————————————————————————————————————————————————— Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range; diff --git a/tests/testthat/_snaps/listing_lbl02a.md b/tests/testthat/_snaps/listing_lbl02a.md index 859cba59..0a8acea2 100644 --- a/tests/testthat/_snaps/listing_lbl02a.md +++ b/tests/testthat/_snaps/listing_lbl02a.md @@ -10,56 +10,56 @@ Study Last Dose of Lab Normal CTCAE Lab Test (Unit) Treatment Center/Patient ID Day Date Study Drug Result Range Grade ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— - Alanine Aminotransferase Measurement (U/L) A: Drug X BRA-1/id-105 80 27MAY2020 0 4.3 7.0 - 55.0 L4 - 398 10APR2021 318 3.7 7.0 - 55.0 L3 - BRA-1/id-93 207 13JAN2021 0 6.1 7.0 - 55.0 L1 - BRA-11/id-397 326 19MAY2021 0 1.5 7.0 - 55.0 L1 - BRA-14/id-23 594 22JUN2021 0 0.6 7.0 - 55.0 L1 - BRA-2/id-296 281 30OCT2021 0 2.6 7.0 - 55.0 L1 - 734 26JAN2023 453 3.9 7.0 - 55.0 L1 - CAN-1/id-18 465 12APR2022 0 1.8 7.0 - 55.0 L2 - CHN-1/id-133 127 13DEC2020 0 5.6 7.0 - 55.0 L2 - 197 21FEB2021 70 1.2 7.0 - 55.0 L4 - CHN-1/id-199 277 11OCT2020 0 5.3 7.0 - 55.0 L4 - 672 10NOV2021 395 6.8 7.0 - 55.0 L2 - CHN-1/id-235 348 25JUN2020 0 3.0 7.0 - 55.0 L3 - 381 28JUL2020 33 4.7 7.0 - 55.0 L1 - CHN-1/id-26 905 07JAN2023 0 1.1 7.0 - 55.0 L1 - CHN-1/id-275 364 01JUN2021 0 5.1 7.0 - 55.0 L2 - CHN-1/id-277 483 12MAY2022 0 1.1 7.0 - 55.0 L4 - CHN-1/id-287 182 23MAY2020 0 5.9 7.0 - 55.0 L2 - 191 01JUN2020 9 5.3 7.0 - 55.0 L3 - 515 21APR2021 324 2.9 7.0 - 55.0 L4 - CHN-1/id-315 289 05JUN2020 0 4.6 7.0 - 55.0 L4 - 599 11APR2021 310 5.2 7.0 - 55.0 L4 - CHN-1/id-316 971 14MAY2023 0 3.6 7.0 - 55.0 L4 - CHN-1/id-360 689 01APR2022 0 4.7 7.0 - 55.0 L2 - CHN-1/id-371 81 01MAY2021 0 5.9 7.0 - 55.0 L2 - CHN-1/id-47 236 11SEP2020 0 4.4 7.0 - 55.0 L3 - CHN-1/id-53 98 13FEB2020 0 6.4 7.0 - 55.0 L2 - 343 15OCT2020 245 3.6 7.0 - 55.0 L2 - CHN-1/id-62 228 08JUL2021 0 5.2 7.0 - 55.0 L4 - CHN-11/id-116 562 28SEP2021 0 5.7 7.0 - 55.0 L3 - CHN-11/id-124 590 23FEB2021 0 6.0 7.0 - 55.0 L3 - CHN-11/id-132 23 21MAR2020 0 3.3 7.0 - 55.0 L2 - CHN-11/id-153 656 31JUL2022 0 1.2 7.0 - 55.0 L1 - CHN-11/id-167 243 08JUL2020 0 5.0 7.0 - 55.0 L4 - CHN-11/id-354 690 31DEC2021 0 3.5 7.0 - 55.0 L2 - CHN-11/id-379 220 06MAR2020 0 2.2 7.0 - 55.0 L3 - CHN-12/id-258 102 11JUN2020 0 0.5 7.0 - 55.0 L3 - 250 06NOV2020 148 0.5 7.0 - 55.0 L2 - CHN-12/id-396 328 13AUG2020 0 5.9 7.0 - 55.0 L2 - CHN-13/id-270 43 29SEP2019 0 2.8 7.0 - 55.0 L3 - 1093 14AUG2022 1050 3.3 7.0 - 55.0 L1 - CHN-14/id-161 123 13JAN2020 0 5.8 7.0 - 55.0 L3 - 440 25NOV2020 317 5.1 7.0 - 55.0 L1 - 875 03FEB2022 435 5.2 7.0 - 55.0 L2 - CHN-14/id-168 251 04FEB2020 0 5.1 7.0 - 55.0 L3 - 303 27MAR2020 52 5.3 7.0 - 55.0 L1 - CHN-14/id-228 448 08JAN2021 0 0.0 7.0 - 55.0 L2 - CHN-15/id-14 265 20JUN2020 0 3.5 7.0 - 55.0 L2 - 272 27JUN2020 7 4.9 7.0 - 55.0 L4 - CHN-15/id-399 310 20AUG2020 0 4.5 7.0 - 55.0 L1 + Alanine Aminotransferase Measurement (U/L) A: Drug X BRA-1/id-105 80 27MAY2020 0 4.3 7.0 - 55.0 L4 + 398 10APR2021 318 3.7 7.0 - 55.0 L3 + BRA-1/id-93 207 13JAN2021 0 6.1 7.0 - 55.0 L1 + BRA-11/id-397 326 19MAY2021 0 1.5 7.0 - 55.0 L1 + BRA-14/id-23 594 22JUN2021 0 0.6 7.0 - 55.0 L1 + BRA-2/id-296 281 30OCT2021 0 2.6 7.0 - 55.0 L1 + 734 26JAN2023 453 3.9 7.0 - 55.0 L1 + CAN-1/id-18 465 12APR2022 0 1.8 7.0 - 55.0 L2 + CHN-1/id-133 127 13DEC2020 0 5.6 7.0 - 55.0 L2 + 197 21FEB2021 70 1.2 7.0 - 55.0 L4 + CHN-1/id-199 277 11OCT2020 0 5.3 7.0 - 55.0 L4 + 672 10NOV2021 395 6.8 7.0 - 55.0 L2 + CHN-1/id-235 348 25JUN2020 0 3.0 7.0 - 55.0 L3 + 381 28JUL2020 33 4.7 7.0 - 55.0 L1 + CHN-1/id-26 905 07JAN2023 0 1.1 7.0 - 55.0 L1 + CHN-1/id-275 364 01JUN2021 0 5.1 7.0 - 55.0 L2 + CHN-1/id-277 483 12MAY2022 0 1.1 7.0 - 55.0 L4 + CHN-1/id-287 182 23MAY2020 0 5.9 7.0 - 55.0 L2 + 191 01JUN2020 9 5.3 7.0 - 55.0 L3 + 515 21APR2021 324 2.9 7.0 - 55.0 L4 + CHN-1/id-315 289 05JUN2020 0 4.6 7.0 - 55.0 L4 + 599 11APR2021 310 5.2 7.0 - 55.0 L4 + CHN-1/id-316 971 14MAY2023 0 3.6 7.0 - 55.0 L4 + CHN-1/id-360 689 01APR2022 0 4.7 7.0 - 55.0 L2 + CHN-1/id-371 81 01MAY2021 0 5.9 7.0 - 55.0 L2 + CHN-1/id-47 236 11SEP2020 0 4.4 7.0 - 55.0 L3 + CHN-1/id-53 98 13FEB2020 0 6.4 7.0 - 55.0 L2 + 343 15OCT2020 245 3.6 7.0 - 55.0 L2 + CHN-1/id-62 228 08JUL2021 0 5.2 7.0 - 55.0 L4 + CHN-11/id-116 562 28SEP2021 0 5.7 7.0 - 55.0 L3 + CHN-11/id-124 590 23FEB2021 0 6.0 7.0 - 55.0 L3 + CHN-11/id-132 23 21MAR2020 0 3.3 7.0 - 55.0 L2 + CHN-11/id-153 656 31JUL2022 0 1.2 7.0 - 55.0 L1 + CHN-11/id-167 243 08JUL2020 0 5.0 7.0 - 55.0 L4 + CHN-11/id-354 690 31DEC2021 0 3.5 7.0 - 55.0 L2 + CHN-11/id-379 220 06MAR2020 0 2.2 7.0 - 55.0 L3 + CHN-12/id-258 102 11JUN2020 0 0.5 7.0 - 55.0 L3 + 250 06NOV2020 148 0.5 7.0 - 55.0 L2 + CHN-12/id-396 328 13AUG2020 0 5.9 7.0 - 55.0 L2 + CHN-13/id-270 43 29SEP2019 0 2.8 7.0 - 55.0 L3 + 1093 14AUG2022 1050 3.3 7.0 - 55.0 L1 + CHN-14/id-161 123 13JAN2020 0 5.8 7.0 - 55.0 L3 + 440 25NOV2020 317 5.1 7.0 - 55.0 L1 + 875 03FEB2022 435 5.2 7.0 - 55.0 L2 + CHN-14/id-168 251 04FEB2020 0 5.1 7.0 - 55.0 L3 + 303 27MAR2020 52 5.3 7.0 - 55.0 L1 + CHN-14/id-228 448 08JAN2021 0 0.0 7.0 - 55.0 L2 + CHN-15/id-14 265 20JUN2020 0 3.5 7.0 - 55.0 L2 + 272 27JUN2020 7 4.9 7.0 - 55.0 L4 + CHN-15/id-399 310 20AUG2020 0 4.5 7.0 - 55.0 L1 ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— NCI CTCAE grade is displayed as abnormal high (H) or low (L) followed by the grade. diff --git a/tests/testthat/_snaps/listing_lbl02a_rls.md b/tests/testthat/_snaps/listing_lbl02a_rls.md index 949cdf71..27678e6c 100644 --- a/tests/testthat/_snaps/listing_lbl02a_rls.md +++ b/tests/testthat/_snaps/listing_lbl02a_rls.md @@ -11,56 +11,56 @@ Study Last Dose of from Reference Reference Change Abnormality Lab Test (Unit) Treatment Center/Patient ID Day Study Drug Result Baseline Range Range Dec./Inc. Flag —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— - Alanine Aminotransferase Measurement (U/L) A: Drug X BRA-1/id-105 80 0 4.3 NA 5.5 - 31.1 7 - 55 40% / 40% LL - 149 69 24.7 0.0 5.5 - 31.1 7 - 55 40% / 40% - 314 165 24.9 0.7 5.5 - 31.1 7 - 55 40% / 40% - 398 84 3.7 -85.2 5.5 - 31.1 7 - 55 40% / 40% LL - 470 72 18.5 -24.9 5.5 - 31.1 7 - 55 40% / 40% - 528 58 7.7 -68.7 5.5 - 31.1 7 - 55 40% / 40% - 535 7 23.5 -4.8 5.5 - 31.1 7 - 55 40% / 40% - BRA-1/id-134 225 0 7.4 NA 5.5 - 31.1 7 - 55 40% / 40% - 227 2 16.4 0.0 5.5 - 31.1 7 - 55 40% / 40% - 255 28 11.2 -32.0 5.5 - 31.1 7 - 55 40% / 40% - 269 14 15.9 -3.2 5.5 - 31.1 7 - 55 40% / 40% - 357 88 24.4 48.3 5.5 - 31.1 7 - 55 40% / 40% - 436 79 16.0 -2.4 5.5 - 31.1 7 - 55 40% / 40% - 440 4 17.2 4.8 5.5 - 31.1 7 - 55 40% / 40% - BRA-1/id-42 176 0 16.6 NA 5.5 - 31.1 7 - 55 40% / 40% - 477 301 16.5 0.0 5.5 - 31.1 7 - 55 40% / 40% - 534 57 18.7 13.4 5.5 - 31.1 7 - 55 40% / 40% - 550 16 11.4 -30.6 5.5 - 31.1 7 - 55 40% / 40% - 569 19 21.7 31.3 5.5 - 31.1 7 - 55 40% / 40% - 608 39 24.6 49.2 5.5 - 31.1 7 - 55 40% / 40% - 675 67 23.5 42.4 5.5 - 31.1 7 - 55 40% / 40% - BRA-1/id-93 19 0 14.7 NA 5.5 - 31.1 7 - 55 40% / 40% - 73 54 15.3 0.0 5.5 - 31.1 7 - 55 40% / 40% - 207 134 6.1 -59.9 5.5 - 31.1 7 - 55 40% / 40% LL - 359 152 17.4 13.7 5.5 - 31.1 7 - 55 40% / 40% - 373 14 15.1 -1.3 5.5 - 31.1 7 - 55 40% / 40% - 422 49 10.0 -35.0 5.5 - 31.1 7 - 55 40% / 40% - 426 4 23.0 49.9 5.5 - 31.1 7 - 55 40% / 40% - BRA-11/id-217 146 0 21.8 NA 5.5 - 31.1 7 - 55 40% / 40% - 320 174 12.5 0.0 5.5 - 31.1 7 - 55 40% / 40% - 442 122 7.3 -41.8 5.5 - 31.1 7 - 55 40% / 40% - 656 214 14.9 19.7 5.5 - 31.1 7 - 55 40% / 40% - 692 36 41.7 234.5 5.5 - 31.1 7 - 55 40% / 40% - 762 70 10.2 -18.0 5.5 - 31.1 7 - 55 40% / 40% - 843 81 14.4 15.5 5.5 - 31.1 7 - 55 40% / 40% - BRA-11/id-345 134 0 26.9 NA 5.5 - 31.1 7 - 55 40% / 40% - 456 322 26.5 0.0 5.5 - 31.1 7 - 55 40% / 40% - 748 292 13.9 -47.4 5.5 - 31.1 7 - 55 40% / 40% - 770 22 20.6 -22.2 5.5 - 31.1 7 - 55 40% / 40% - 855 85 26.8 1.2 5.5 - 31.1 7 - 55 40% / 40% - 882 27 18.6 -29.8 5.5 - 31.1 7 - 55 40% / 40% - 954 72 10.1 -62.1 5.5 - 31.1 7 - 55 40% / 40% - BRA-11/id-397 311 0 9.5 NA 5.5 - 31.1 7 - 55 40% / 40% - 326 15 1.5 0.0 5.5 - 31.1 7 - 55 40% / 40% LL - 500 174 12.5 731.3 5.5 - 31.1 7 - 55 40% / 40% - 566 66 7.8 421.7 5.5 - 31.1 7 - 55 40% / 40% - 608 42 27.7 1749.2 5.5 - 31.1 7 - 55 40% / 40% - 725 117 32.6 2070.7 5.5 - 31.1 7 - 55 40% / 40% - 1026 301 19.7 1211.7 5.5 - 31.1 7 - 55 40% / 40% - BRA-11/id-50 72 0 21.9 NA 5.5 - 31.1 7 - 55 40% / 40% + Alanine Aminotransferase Measurement (U/L) A: Drug X BRA-1/id-105 80 0 4.3 NA 5.5 - 31.1 7 - 55 40% / 40% LL + 149 69 24.7 0.0 5.5 - 31.1 7 - 55 40% / 40% + 314 165 24.9 0.7 5.5 - 31.1 7 - 55 40% / 40% + 398 84 3.7 -85.2 5.5 - 31.1 7 - 55 40% / 40% LL + 470 72 18.5 -24.9 5.5 - 31.1 7 - 55 40% / 40% + 528 58 7.7 -68.7 5.5 - 31.1 7 - 55 40% / 40% + 535 7 23.5 -4.8 5.5 - 31.1 7 - 55 40% / 40% + BRA-1/id-134 225 0 7.4 NA 5.5 - 31.1 7 - 55 40% / 40% + 227 2 16.4 0.0 5.5 - 31.1 7 - 55 40% / 40% + 255 28 11.2 -32.0 5.5 - 31.1 7 - 55 40% / 40% + 269 14 15.9 -3.2 5.5 - 31.1 7 - 55 40% / 40% + 357 88 24.4 48.3 5.5 - 31.1 7 - 55 40% / 40% + 436 79 16.0 -2.4 5.5 - 31.1 7 - 55 40% / 40% + 440 4 17.2 4.8 5.5 - 31.1 7 - 55 40% / 40% + BRA-1/id-42 176 0 16.6 NA 5.5 - 31.1 7 - 55 40% / 40% + 477 301 16.5 0.0 5.5 - 31.1 7 - 55 40% / 40% + 534 57 18.7 13.4 5.5 - 31.1 7 - 55 40% / 40% + 550 16 11.4 -30.6 5.5 - 31.1 7 - 55 40% / 40% + 569 19 21.7 31.3 5.5 - 31.1 7 - 55 40% / 40% + 608 39 24.6 49.2 5.5 - 31.1 7 - 55 40% / 40% + 675 67 23.5 42.4 5.5 - 31.1 7 - 55 40% / 40% + BRA-1/id-93 19 0 14.7 NA 5.5 - 31.1 7 - 55 40% / 40% + 73 54 15.3 0.0 5.5 - 31.1 7 - 55 40% / 40% + 207 134 6.1 -59.9 5.5 - 31.1 7 - 55 40% / 40% LL + 359 152 17.4 13.7 5.5 - 31.1 7 - 55 40% / 40% + 373 14 15.1 -1.3 5.5 - 31.1 7 - 55 40% / 40% + 422 49 10.0 -35.0 5.5 - 31.1 7 - 55 40% / 40% + 426 4 23.0 49.9 5.5 - 31.1 7 - 55 40% / 40% + BRA-11/id-217 146 0 21.8 NA 5.5 - 31.1 7 - 55 40% / 40% + 320 174 12.5 0.0 5.5 - 31.1 7 - 55 40% / 40% + 442 122 7.3 -41.8 5.5 - 31.1 7 - 55 40% / 40% + 656 214 14.9 19.7 5.5 - 31.1 7 - 55 40% / 40% + 692 36 41.7 234.5 5.5 - 31.1 7 - 55 40% / 40% + 762 70 10.2 -18.0 5.5 - 31.1 7 - 55 40% / 40% + 843 81 14.4 15.5 5.5 - 31.1 7 - 55 40% / 40% + BRA-11/id-345 134 0 26.9 NA 5.5 - 31.1 7 - 55 40% / 40% + 456 322 26.5 0.0 5.5 - 31.1 7 - 55 40% / 40% + 748 292 13.9 -47.4 5.5 - 31.1 7 - 55 40% / 40% + 770 22 20.6 -22.2 5.5 - 31.1 7 - 55 40% / 40% + 855 85 26.8 1.2 5.5 - 31.1 7 - 55 40% / 40% + 882 27 18.6 -29.8 5.5 - 31.1 7 - 55 40% / 40% + 954 72 10.1 -62.1 5.5 - 31.1 7 - 55 40% / 40% + BRA-11/id-397 311 0 9.5 NA 5.5 - 31.1 7 - 55 40% / 40% + 326 15 1.5 0.0 5.5 - 31.1 7 - 55 40% / 40% LL + 500 174 12.5 731.3 5.5 - 31.1 7 - 55 40% / 40% + 566 66 7.8 421.7 5.5 - 31.1 7 - 55 40% / 40% + 608 42 27.7 1749.2 5.5 - 31.1 7 - 55 40% / 40% + 725 117 32.6 2070.7 5.5 - 31.1 7 - 55 40% / 40% + 1026 301 19.7 1211.7 5.5 - 31.1 7 - 55 40% / 40% + BRA-11/id-50 72 0 21.9 NA 5.5 - 31.1 7 - 55 40% / 40% —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— Standard reference range, marked reference range and clinically relevant change from baseline are from the Roche Safety Lab Standardization guideline. Abnormalities are flagged as high (H) or low (L) if outside the standard reference range; high high (HH) or low low (LL) if outside the marked reference range with a clinically relevant change from baseline. diff --git a/tests/testthat/_snaps/listing_lbl02b.md b/tests/testthat/_snaps/listing_lbl02b.md index 3a1cc275..f927f50f 100644 --- a/tests/testthat/_snaps/listing_lbl02b.md +++ b/tests/testthat/_snaps/listing_lbl02b.md @@ -10,56 +10,56 @@ Study Last Dose of Lab Normal CTCAE Lab Test Treatment Center/Patient ID Day Date Study Drug Result Unit Range Grade ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— - Alanine Aminotransferase Measurement A: Drug X BRA-1/id-105 80 27MAY2020 0 4.3 U/L 7.0 - 55.0 L4 - 398 10APR2021 318 3.7 U/L 7.0 - 55.0 L3 - CAN-1/id-18 465 12APR2022 0 1.8 U/L 7.0 - 55.0 L2 - CHN-1/id-133 127 13DEC2020 0 5.6 U/L 7.0 - 55.0 L2 - 197 21FEB2021 70 1.2 U/L 7.0 - 55.0 L4 - CHN-1/id-199 277 11OCT2020 0 5.3 U/L 7.0 - 55.0 L4 - 672 10NOV2021 395 6.8 U/L 7.0 - 55.0 L2 - CHN-1/id-235 348 25JUN2020 0 3.0 U/L 7.0 - 55.0 L3 - CHN-1/id-275 364 01JUN2021 0 5.1 U/L 7.0 - 55.0 L2 - CHN-1/id-277 483 12MAY2022 0 1.1 U/L 7.0 - 55.0 L4 - CHN-1/id-287 182 23MAY2020 0 5.9 U/L 7.0 - 55.0 L2 - 191 01JUN2020 9 5.3 U/L 7.0 - 55.0 L3 - 515 21APR2021 324 2.9 U/L 7.0 - 55.0 L4 - CHN-1/id-315 289 05JUN2020 0 4.6 U/L 7.0 - 55.0 L4 - 599 11APR2021 310 5.2 U/L 7.0 - 55.0 L4 - CHN-1/id-316 971 14MAY2023 0 3.6 U/L 7.0 - 55.0 L4 - CHN-1/id-360 689 01APR2022 0 4.7 U/L 7.0 - 55.0 L2 - CHN-1/id-371 81 01MAY2021 0 5.9 U/L 7.0 - 55.0 L2 - CHN-1/id-47 236 11SEP2020 0 4.4 U/L 7.0 - 55.0 L3 - CHN-1/id-53 98 13FEB2020 0 6.4 U/L 7.0 - 55.0 L2 - 343 15OCT2020 245 3.6 U/L 7.0 - 55.0 L2 - CHN-1/id-62 228 08JUL2021 0 5.2 U/L 7.0 - 55.0 L4 - CHN-11/id-116 562 28SEP2021 0 5.7 U/L 7.0 - 55.0 L3 - CHN-11/id-124 590 23FEB2021 0 6.0 U/L 7.0 - 55.0 L3 - CHN-11/id-132 23 21MAR2020 0 3.3 U/L 7.0 - 55.0 L2 - CHN-11/id-167 243 08JUL2020 0 5.0 U/L 7.0 - 55.0 L4 - CHN-11/id-354 690 31DEC2021 0 3.5 U/L 7.0 - 55.0 L2 - CHN-11/id-379 220 06MAR2020 0 2.2 U/L 7.0 - 55.0 L3 - CHN-12/id-258 102 11JUN2020 0 0.5 U/L 7.0 - 55.0 L3 - 250 06NOV2020 148 0.5 U/L 7.0 - 55.0 L2 - CHN-12/id-396 328 13AUG2020 0 5.9 U/L 7.0 - 55.0 L2 - CHN-13/id-270 43 29SEP2019 0 2.8 U/L 7.0 - 55.0 L3 - CHN-14/id-161 123 13JAN2020 0 5.8 U/L 7.0 - 55.0 L3 - 875 03FEB2022 752 5.2 U/L 7.0 - 55.0 L2 - CHN-14/id-168 251 04FEB2020 0 5.1 U/L 7.0 - 55.0 L3 - CHN-14/id-228 448 08JAN2021 0 0.0 U/L 7.0 - 55.0 L2 - CHN-15/id-14 265 20JUN2020 0 3.5 U/L 7.0 - 55.0 L2 - 272 27JUN2020 7 4.9 U/L 7.0 - 55.0 L4 - CHN-17/id-182 522 21FEB2021 0 3.2 U/L 7.0 - 55.0 L4 - CHN-17/id-209 688 04NOV2022 0 1.2 U/L 7.0 - 55.0 L2 - CHN-17/id-309 344 05APR2020 0 0.4 U/L 7.0 - 55.0 L2 - CHN-2/id-22 79 04APR2021 0 3.3 U/L 7.0 - 55.0 L2 - 81 06APR2021 2 0.7 U/L 7.0 - 55.0 L4 - CHN-2/id-286 116 09SEP2019 0 3.4 U/L 7.0 - 55.0 L3 - 645 19FEB2021 529 1.8 U/L 7.0 - 55.0 L3 - CHN-2/id-367 220 02FEB2021 0 5.9 U/L 7.0 - 55.0 L4 - CHN-2/id-395 939 21NOV2021 0 4.0 U/L 7.0 - 55.0 L4 - CHN-2/id-398 299 13AUG2020 0 0.1 U/L 7.0 - 55.0 L2 - CHN-3/id-128 151 25JUL2019 0 2.4 U/L 7.0 - 55.0 L2 - 313 03JAN2020 162 6.6 U/L 7.0 - 55.0 L4 + Alanine Aminotransferase Measurement A: Drug X BRA-1/id-105 80 27MAY2020 0 4.3 U/L 7.0 - 55.0 L4 + 398 10APR2021 318 3.7 U/L 7.0 - 55.0 L3 + CAN-1/id-18 465 12APR2022 0 1.8 U/L 7.0 - 55.0 L2 + CHN-1/id-133 127 13DEC2020 0 5.6 U/L 7.0 - 55.0 L2 + 197 21FEB2021 70 1.2 U/L 7.0 - 55.0 L4 + CHN-1/id-199 277 11OCT2020 0 5.3 U/L 7.0 - 55.0 L4 + 672 10NOV2021 395 6.8 U/L 7.0 - 55.0 L2 + CHN-1/id-235 348 25JUN2020 0 3.0 U/L 7.0 - 55.0 L3 + CHN-1/id-275 364 01JUN2021 0 5.1 U/L 7.0 - 55.0 L2 + CHN-1/id-277 483 12MAY2022 0 1.1 U/L 7.0 - 55.0 L4 + CHN-1/id-287 182 23MAY2020 0 5.9 U/L 7.0 - 55.0 L2 + 191 01JUN2020 9 5.3 U/L 7.0 - 55.0 L3 + 515 21APR2021 324 2.9 U/L 7.0 - 55.0 L4 + CHN-1/id-315 289 05JUN2020 0 4.6 U/L 7.0 - 55.0 L4 + 599 11APR2021 310 5.2 U/L 7.0 - 55.0 L4 + CHN-1/id-316 971 14MAY2023 0 3.6 U/L 7.0 - 55.0 L4 + CHN-1/id-360 689 01APR2022 0 4.7 U/L 7.0 - 55.0 L2 + CHN-1/id-371 81 01MAY2021 0 5.9 U/L 7.0 - 55.0 L2 + CHN-1/id-47 236 11SEP2020 0 4.4 U/L 7.0 - 55.0 L3 + CHN-1/id-53 98 13FEB2020 0 6.4 U/L 7.0 - 55.0 L2 + 343 15OCT2020 245 3.6 U/L 7.0 - 55.0 L2 + CHN-1/id-62 228 08JUL2021 0 5.2 U/L 7.0 - 55.0 L4 + CHN-11/id-116 562 28SEP2021 0 5.7 U/L 7.0 - 55.0 L3 + CHN-11/id-124 590 23FEB2021 0 6.0 U/L 7.0 - 55.0 L3 + CHN-11/id-132 23 21MAR2020 0 3.3 U/L 7.0 - 55.0 L2 + CHN-11/id-167 243 08JUL2020 0 5.0 U/L 7.0 - 55.0 L4 + CHN-11/id-354 690 31DEC2021 0 3.5 U/L 7.0 - 55.0 L2 + CHN-11/id-379 220 06MAR2020 0 2.2 U/L 7.0 - 55.0 L3 + CHN-12/id-258 102 11JUN2020 0 0.5 U/L 7.0 - 55.0 L3 + 250 06NOV2020 148 0.5 U/L 7.0 - 55.0 L2 + CHN-12/id-396 328 13AUG2020 0 5.9 U/L 7.0 - 55.0 L2 + CHN-13/id-270 43 29SEP2019 0 2.8 U/L 7.0 - 55.0 L3 + CHN-14/id-161 123 13JAN2020 0 5.8 U/L 7.0 - 55.0 L3 + 875 03FEB2022 752 5.2 U/L 7.0 - 55.0 L2 + CHN-14/id-168 251 04FEB2020 0 5.1 U/L 7.0 - 55.0 L3 + CHN-14/id-228 448 08JAN2021 0 0.0 U/L 7.0 - 55.0 L2 + CHN-15/id-14 265 20JUN2020 0 3.5 U/L 7.0 - 55.0 L2 + 272 27JUN2020 7 4.9 U/L 7.0 - 55.0 L4 + CHN-17/id-182 522 21FEB2021 0 3.2 U/L 7.0 - 55.0 L4 + CHN-17/id-209 688 04NOV2022 0 1.2 U/L 7.0 - 55.0 L2 + CHN-17/id-309 344 05APR2020 0 0.4 U/L 7.0 - 55.0 L2 + CHN-2/id-22 79 04APR2021 0 3.3 U/L 7.0 - 55.0 L2 + 81 06APR2021 2 0.7 U/L 7.0 - 55.0 L4 + CHN-2/id-286 116 09SEP2019 0 3.4 U/L 7.0 - 55.0 L3 + 645 19FEB2021 529 1.8 U/L 7.0 - 55.0 L3 + CHN-2/id-367 220 02FEB2021 0 5.9 U/L 7.0 - 55.0 L4 + CHN-2/id-395 939 21NOV2021 0 4.0 U/L 7.0 - 55.0 L4 + CHN-2/id-398 299 13AUG2020 0 0.1 U/L 7.0 - 55.0 L2 + CHN-3/id-128 151 25JUL2019 0 2.4 U/L 7.0 - 55.0 L2 + 313 03JAN2020 162 6.6 U/L 7.0 - 55.0 L4 ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— NCI CTCAE grade is displayed as abnormal high (H) or low (L) followed by the grade. diff --git a/tests/testthat/_snaps/listing_oncl01.md b/tests/testthat/_snaps/listing_oncl01.md index 215d75c8..9d6ca6fa 100644 --- a/tests/testthat/_snaps/listing_oncl01.md +++ b/tests/testthat/_snaps/listing_oncl01.md @@ -11,9 +11,9 @@ BRA-1/id-105 A: Drug X 7 CR CR 402.6 235.7 Disease Progression 119.6 7 CR CR 402.6 235.7 NA 119.6 7 CR CR 402.6 235.7 NA 119.6 - BRA-1/id-134 A: Drug X 7 CR CR 90.1 90.1 Death 90.1 - 7 CR CR 90.1 90.1 Death 90.1 - 7 CR CR 90.1 90.1 Death 90.1 + BRA-1/id-134 A: Drug X 7 CR CR 90.1 90.1 Death 90.1 + 7 CR CR 90.1 90.1 Death 90.1 + 7 CR CR 90.1 90.1 Death 90.1 BRA-1/id-141 C: Combination 7 CR PR 422.9 216.3 NA 123.0 7 CR PR 422.9 216.3 NA 123.0 7 CR PR 422.9 216.3 NA 123.0 diff --git a/tests/testthat/_snaps/listing_vsl01.md b/tests/testthat/_snaps/listing_vsl01.md index ebc20aa0..eea36cd6 100644 --- a/tests/testthat/_snaps/listing_vsl01.md +++ b/tests/testthat/_snaps/listing_vsl01.md @@ -13,56 +13,56 @@ Study (Kg); Weight (C); Temperature Rate (Pa); Sitting (Pa); Sitting (beats/min); Pulse Rate (breaths/min); Respiratory Rate Center/Subject ID Age/Sex/Race Treatment Visit Day Range:(40-100) Change from BL Range:(36.1-37.2) Change from BL Range:(80-120) Change from BL Range:(120-180) Change from BL Range:(60-100) Change from BL Range:(12-20) Change from BL ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— - BRA-1/105 38/M/BLACK OR AFRICAN AMERICAN A: Drug X SCREENING 18 102.15/H NA 37.22/H NA 72.60/L NA 157.75 NA 84.41 NA 25.27/H NA - BASELINE 19 66.34 0.00 38.66/H 0.00 113.74 0.00 177.35 0.00 86.96 0.00 17.21 0.00 - WEEK 1 DAY 8 189 90.96 24.62 36.79 -1.88 101.10 -12.65 181.05/H 3.70 84.91 -2.05 18.34 1.13 - WEEK 2 DAY 15 323 41.40 -24.93 36.52 -2.14 111.02 -2.72 132.47 -44.88 71.54 -15.42 9.81/L -7.40 - WEEK 3 DAY 22 492 60.55 -5.78 35.03/L -3.64 88.35 -25.39 112.67/L -64.68 33.75/L -53.22 21.23/H 4.02 - WEEK 4 DAY 29 550 69.69 3.36 35.71/L -2.95 100.74 -13.00 194.88/H 17.53 97.51 10.54 12.50 -4.71 - WEEK 5 DAY 36 628 81.64 15.30 36.01/L -2.65 123.17/H 9.43 140.33 -37.02 62.50 -24.47 10.91/L -6.30 - BRA-1/134 47/M/WHITE A: Drug X SCREENING 46 73.65 NA 36.65 NA 78.73/L NA 158.65 NA 95.99 NA 20.10/H NA - BASELINE 80 55.46 0.00 37.77/H 0.00 86.32 0.00 201.44/H 0.00 65.40 0.00 18.14 0.00 - WEEK 1 DAY 8 203 42.95 -12.51 36.39 -1.38 112.71 26.38 148.69 -52.75 69.12 3.72 15.31 -2.84 - WEEK 2 DAY 15 326 20.36/L -35.09 35.75/L -2.03 98.42 12.09 188.08/H -13.36 68.79 3.40 17.60 -0.55 - WEEK 3 DAY 22 363 46.33 -9.12 35.43/L -2.34 97.88 11.55 160.05 -41.39 90.21 24.81 18.15 0.00 - WEEK 4 DAY 29 367 43.83 -11.62 36.01/L -1.76 98.97 12.65 132.19 -69.25 88.39 23.00 19.62 1.48 - WEEK 5 DAY 36 417 31.75/L -23.71 36.35 -1.42 124.26/H 37.94 134.30 -67.14 88.64 23.25 20.08/H 1.94 - BRA-1/141 35/F/WHITE C: Combination SCREENING 2 75.85 NA 36.84 NA 86.64 NA 149.65 NA 101.32/H NA 16.89 NA - BASELINE 456 56.10 0.00 37.01 0.00 129.46/H 0.00 136.77 0.00 76.32 0.00 11.02/L 0.00 - WEEK 1 DAY 8 515 65.32 9.22 36.72 -0.29 81.16 -48.30 73.44/L -63.33 99.83 23.51 21.66/H 10.64 - WEEK 2 DAY 15 764 87.53 31.44 37.68/H 0.67 110.55 -18.90 172.75 35.98 114.23/H 37.92 16.13 5.10 - WEEK 3 DAY 22 814 69.69 13.59 38.39/H 1.38 69.94/L -59.52 155.35 18.58 88.12 11.80 15.31 4.29 - WEEK 4 DAY 29 844 74.64 18.54 36.62 -0.40 84.59 -44.87 156.15 19.38 71.44 -4.87 12.20 1.18 - WEEK 5 DAY 36 914 39.39/L -16.71 36.81 -0.21 102.02 -27.44 135.87 -0.90 68.75 -7.56 9.76/L -1.26 - BRA-1/236 32/M/BLACK OR AFRICAN AMERICAN B: Placebo SCREENING 20 87.21 NA 36.03/L NA 98.87 NA 152.75 NA 71.63 NA 17.11 NA - BASELINE 459 37.83/L 0.00 35.84/L 0.00 108.57 0.00 151.13 0.00 69.08 0.00 18.73 0.00 - WEEK 1 DAY 8 486 37.04/L -0.79 36.11 0.27 120.31/H 11.74 146.04 -5.09 65.75 -3.33 22.69/H 3.96 - WEEK 2 DAY 15 678 80.66 42.83 35.64/L -0.21 106.20 -2.37 146.80 -4.32 82.04 12.96 16.89 -1.84 - WEEK 3 DAY 22 762 86.71 48.88 36.16 0.32 104.63 -3.94 76.01/L -75.12 70.13 1.05 19.70 0.97 - WEEK 4 DAY 29 773 48.43 10.60 35.38/L -0.47 111.13 2.56 134.79 -16.34 80.78 11.70 17.98 -0.75 - WEEK 5 DAY 36 901 24.05/L -13.78 35.90/L 0.05 108.01 -0.56 137.95 -13.17 68.35 -0.73 8.48/L -10.25 - BRA-1/265 25/M/WHITE C: Combination SCREENING 211 73.94 NA 37.21/H NA 128.65/H NA 160.40 NA 91.18 NA 21.25/H NA - BASELINE 451 56.39 0.00 36.32 0.00 85.59 0.00 113.02/L 0.00 73.44 0.00 19.27 0.00 - WEEK 1 DAY 8 472 77.08 20.70 38.91/H 2.59 81.50 -4.10 159.36 46.34 84.91 11.48 19.08 -0.19 - WEEK 2 DAY 15 537 79.52 23.14 37.48/H 1.16 99.58 13.99 97.34/L -15.68 95.33 21.89 14.10 -5.18 - WEEK 3 DAY 22 596 70.63 14.24 35.56/L -0.77 77.12/L -8.47 177.87 64.86 60.20 -13.23 24.98/H 5.71 - WEEK 4 DAY 29 612 118.85/H 62.46 36.66 0.34 88.13 2.54 90.78/L -22.24 58.01/L -15.42 10.62/L -8.66 - WEEK 5 DAY 36 695 57.46 1.07 36.37 0.05 98.18 12.59 144.83 31.82 76.02 2.58 19.58 0.31 - BRA-1/42 36/M/BLACK OR AFRICAN AMERICAN A: Drug X SCREENING 17 60.78 NA 37.46/H NA 97.11 NA 185.20/H NA 70.51 NA 9.26/L NA - BASELINE 235 106.85/H 0.00 39.02/H 0.00 101.42 0.00 146.49 0.00 40.01/L 0.00 2.10/L 0.00 - WEEK 1 DAY 8 265 115.27/H 8.42 37.35/H -1.67 107.32 5.90 173.89 27.40 66.14 26.13 9.23/L 7.13 - WEEK 2 DAY 15 313 45.84 -61.01 36.01/L -3.01 110.97 9.55 144.75 -1.74 109.71/H 69.70 7.18/L 5.08 - WEEK 3 DAY 22 325 85.70 -21.14 37.71/H -1.31 124.13/H 22.71 89.08/L -57.41 90.29 50.28 25.16/H 23.05 - WEEK 4 DAY 29 535 44.64 -62.21 36.44 -2.58 79.51/L -21.91 140.78 -5.71 82.44 42.43 14.06 11.95 - WEEK 5 DAY 36 729 85.21 -21.64 35.78/L -3.23 105.26 3.84 126.60 -19.89 88.71 48.70 25.98/H 23.87 - BRA-1/65 25/F/BLACK OR AFRICAN AMERICAN B: Placebo SCREENING 322 81.66 NA 36.74 NA 63.90/L NA 188.10/H NA 90.18 NA 16.59 NA - BASELINE 386 72.59 0.00 36.56 0.00 80.37 0.00 173.19 0.00 80.20 0.00 16.47 0.00 - WEEK 1 DAY 8 546 60.68 -11.91 34.67/L -1.89 113.72 33.35 132.45 -40.74 76.37 -3.82 16.70 0.22 - WEEK 2 DAY 15 604 55.85 -16.74 38.63/H 2.07 127.03/H 46.67 133.52 -39.67 93.95 13.75 15.08 -1.39 - WEEK 3 DAY 22 723 47.66 -24.92 37.02 0.46 116.06 35.69 91.36/L -81.83 62.00 -18.20 3.89/L -12.58 - WEEK 4 DAY 29 791 116.89/H 44.30 37.90/H 1.34 113.53 33.17 170.65 -2.53 96.86 16.66 6.73/L -9.74 - WEEK 5 DAY 36 800 56.73 -15.85 36.81 0.25 141.54/H 61.17 165.15 -8.03 75.85 -4.35 23.02/H 6.55 - BRA-1/93 34/F/ASIAN A: Drug X SCREENING 140 88.69 NA 37.31/H NA 93.38 NA 176.70 NA 53.90/L NA 14.72 NA + BRA-1/105 38/M/BLACK OR AFRICAN AMERICAN A: Drug X SCREENING 18 102.15/H NA 37.22/H NA 72.60/L NA 157.75 NA 84.41 NA 25.27/H NA + BASELINE 19 66.34 0.00 38.66/H 0.00 113.74 0.00 177.35 0.00 86.96 0.00 17.21 0.00 + WEEK 1 DAY 8 189 90.96 24.62 36.79 -1.88 101.10 -12.65 181.05/H 3.70 84.91 -2.05 18.34 1.13 + WEEK 2 DAY 15 323 41.40 -24.93 36.52 -2.14 111.02 -2.72 132.47 -44.88 71.54 -15.42 9.81/L -7.40 + WEEK 3 DAY 22 492 60.55 -5.78 35.03/L -3.64 88.35 -25.39 112.67/L -64.68 33.75/L -53.22 21.23/H 4.02 + WEEK 4 DAY 29 550 69.69 3.36 35.71/L -2.95 100.74 -13.00 194.88/H 17.53 97.51 10.54 12.50 -4.71 + WEEK 5 DAY 36 628 81.64 15.30 36.01/L -2.65 123.17/H 9.43 140.33 -37.02 62.50 -24.47 10.91/L -6.30 + BRA-1/134 47/M/WHITE A: Drug X SCREENING 46 73.65 NA 36.65 NA 78.73/L NA 158.65 NA 95.99 NA 20.10/H NA + BASELINE 80 55.46 0.00 37.77/H 0.00 86.32 0.00 201.44/H 0.00 65.40 0.00 18.14 0.00 + WEEK 1 DAY 8 203 42.95 -12.51 36.39 -1.38 112.71 26.38 148.69 -52.75 69.12 3.72 15.31 -2.84 + WEEK 2 DAY 15 326 20.36/L -35.09 35.75/L -2.03 98.42 12.09 188.08/H -13.36 68.79 3.40 17.60 -0.55 + WEEK 3 DAY 22 363 46.33 -9.12 35.43/L -2.34 97.88 11.55 160.05 -41.39 90.21 24.81 18.15 0.00 + WEEK 4 DAY 29 367 43.83 -11.62 36.01/L -1.76 98.97 12.65 132.19 -69.25 88.39 23.00 19.62 1.48 + WEEK 5 DAY 36 417 31.75/L -23.71 36.35 -1.42 124.26/H 37.94 134.30 -67.14 88.64 23.25 20.08/H 1.94 + BRA-1/141 35/F/WHITE C: Combination SCREENING 2 75.85 NA 36.84 NA 86.64 NA 149.65 NA 101.32/H NA 16.89 NA + BASELINE 456 56.10 0.00 37.01 0.00 129.46/H 0.00 136.77 0.00 76.32 0.00 11.02/L 0.00 + WEEK 1 DAY 8 515 65.32 9.22 36.72 -0.29 81.16 -48.30 73.44/L -63.33 99.83 23.51 21.66/H 10.64 + WEEK 2 DAY 15 764 87.53 31.44 37.68/H 0.67 110.55 -18.90 172.75 35.98 114.23/H 37.92 16.13 5.10 + WEEK 3 DAY 22 814 69.69 13.59 38.39/H 1.38 69.94/L -59.52 155.35 18.58 88.12 11.80 15.31 4.29 + WEEK 4 DAY 29 844 74.64 18.54 36.62 -0.40 84.59 -44.87 156.15 19.38 71.44 -4.87 12.20 1.18 + WEEK 5 DAY 36 914 39.39/L -16.71 36.81 -0.21 102.02 -27.44 135.87 -0.90 68.75 -7.56 9.76/L -1.26 + BRA-1/236 32/M/BLACK OR AFRICAN AMERICAN B: Placebo SCREENING 20 87.21 NA 36.03/L NA 98.87 NA 152.75 NA 71.63 NA 17.11 NA + BASELINE 459 37.83/L 0.00 35.84/L 0.00 108.57 0.00 151.13 0.00 69.08 0.00 18.73 0.00 + WEEK 1 DAY 8 486 37.04/L -0.79 36.11 0.27 120.31/H 11.74 146.04 -5.09 65.75 -3.33 22.69/H 3.96 + WEEK 2 DAY 15 678 80.66 42.83 35.64/L -0.21 106.20 -2.37 146.80 -4.32 82.04 12.96 16.89 -1.84 + WEEK 3 DAY 22 762 86.71 48.88 36.16 0.32 104.63 -3.94 76.01/L -75.12 70.13 1.05 19.70 0.97 + WEEK 4 DAY 29 773 48.43 10.60 35.38/L -0.47 111.13 2.56 134.79 -16.34 80.78 11.70 17.98 -0.75 + WEEK 5 DAY 36 901 24.05/L -13.78 35.90/L 0.05 108.01 -0.56 137.95 -13.17 68.35 -0.73 8.48/L -10.25 + BRA-1/265 25/M/WHITE C: Combination SCREENING 211 73.94 NA 37.21/H NA 128.65/H NA 160.40 NA 91.18 NA 21.25/H NA + BASELINE 451 56.39 0.00 36.32 0.00 85.59 0.00 113.02/L 0.00 73.44 0.00 19.27 0.00 + WEEK 1 DAY 8 472 77.08 20.70 38.91/H 2.59 81.50 -4.10 159.36 46.34 84.91 11.48 19.08 -0.19 + WEEK 2 DAY 15 537 79.52 23.14 37.48/H 1.16 99.58 13.99 97.34/L -15.68 95.33 21.89 14.10 -5.18 + WEEK 3 DAY 22 596 70.63 14.24 35.56/L -0.77 77.12/L -8.47 177.87 64.86 60.20 -13.23 24.98/H 5.71 + WEEK 4 DAY 29 612 118.85/H 62.46 36.66 0.34 88.13 2.54 90.78/L -22.24 58.01/L -15.42 10.62/L -8.66 + WEEK 5 DAY 36 695 57.46 1.07 36.37 0.05 98.18 12.59 144.83 31.82 76.02 2.58 19.58 0.31 + BRA-1/42 36/M/BLACK OR AFRICAN AMERICAN A: Drug X SCREENING 17 60.78 NA 37.46/H NA 97.11 NA 185.20/H NA 70.51 NA 9.26/L NA + BASELINE 235 106.85/H 0.00 39.02/H 0.00 101.42 0.00 146.49 0.00 40.01/L 0.00 2.10/L 0.00 + WEEK 1 DAY 8 265 115.27/H 8.42 37.35/H -1.67 107.32 5.90 173.89 27.40 66.14 26.13 9.23/L 7.13 + WEEK 2 DAY 15 313 45.84 -61.01 36.01/L -3.01 110.97 9.55 144.75 -1.74 109.71/H 69.70 7.18/L 5.08 + WEEK 3 DAY 22 325 85.70 -21.14 37.71/H -1.31 124.13/H 22.71 89.08/L -57.41 90.29 50.28 25.16/H 23.05 + WEEK 4 DAY 29 535 44.64 -62.21 36.44 -2.58 79.51/L -21.91 140.78 -5.71 82.44 42.43 14.06 11.95 + WEEK 5 DAY 36 729 85.21 -21.64 35.78/L -3.23 105.26 3.84 126.60 -19.89 88.71 48.70 25.98/H 23.87 + BRA-1/65 25/F/BLACK OR AFRICAN AMERICAN B: Placebo SCREENING 322 81.66 NA 36.74 NA 63.90/L NA 188.10/H NA 90.18 NA 16.59 NA + BASELINE 386 72.59 0.00 36.56 0.00 80.37 0.00 173.19 0.00 80.20 0.00 16.47 0.00 + WEEK 1 DAY 8 546 60.68 -11.91 34.67/L -1.89 113.72 33.35 132.45 -40.74 76.37 -3.82 16.70 0.22 + WEEK 2 DAY 15 604 55.85 -16.74 38.63/H 2.07 127.03/H 46.67 133.52 -39.67 93.95 13.75 15.08 -1.39 + WEEK 3 DAY 22 723 47.66 -24.92 37.02 0.46 116.06 35.69 91.36/L -81.83 62.00 -18.20 3.89/L -12.58 + WEEK 4 DAY 29 791 116.89/H 44.30 37.90/H 1.34 113.53 33.17 170.65 -2.53 96.86 16.66 6.73/L -9.74 + WEEK 5 DAY 36 800 56.73 -15.85 36.81 0.25 141.54/H 61.17 165.15 -8.03 75.85 -4.35 23.02/H 6.55 + BRA-1/93 34/F/ASIAN A: Drug X SCREENING 140 88.69 NA 37.31/H NA 93.38 NA 176.70 NA 53.90/L NA 14.72 NA ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————— Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are diff --git a/tests/testthat/_snaps/pagination_table.md b/tests/testthat/_snaps/pagination_table.md index bc655fba..f4d950c9 100644 --- a/tests/testthat/_snaps/pagination_table.md +++ b/tests/testthat/_snaps/pagination_table.md @@ -80,7 +80,7 @@ - 50 45 63 (47.7%) Any (37.3%) (33.6%) Grad - e - + e Grad 50 45 63 (47.7%) e (37.3%) (33.6%) 1-2 @@ -92,7 +92,7 @@ - 48 48 50 (37.9%) Any (35.8%) (35.8%) Grad - e - + e Grad 48 48 50 (37.9%) e (35.8%) (35.8%) 1-2 @@ -141,7 +141,7 @@ - 48 42 50 (37.9%) Any (35.8%) (31.3%) Grad - e - + e Grad 48 42 50 (37.9%) e (35.8%) (31.3%) 3-4 @@ -160,7 +160,7 @@ - 47 58 57 (43.2%) Any (35.1%) (43.3%) Grad - e - + e Grad 47 58 57 (43.2%) e (35.1%) (43.3%) 1-2 @@ -177,7 +177,7 @@ - 47 49 43 (32.6%) Any (35.1%) (36.6%) Grad - e - + e Grad 47 49 43 (32.6%) e 5 (35.1%) (36.6%) ————————————————————————————————————————————— @@ -220,7 +220,7 @@ - 48 48 50 (37.9%) Any (35.8%) (35.8%) Grad - e - + e Grad 48 48 50 (37.9%) e (35.8%) (35.8%) 1-2 diff --git a/tests/testthat/_snaps/table_coxt01.md b/tests/testthat/_snaps/table_coxt01.md index b308e9fa..1ed10a8f 100644 --- a/tests/testthat/_snaps/table_coxt01.md +++ b/tests/testthat/_snaps/table_coxt01.md @@ -17,62 +17,62 @@ Code res Output - n Hazard Ratio 95% CI p-value Interaction p-value - ——————————————————————————————————————————————————————————————————————————————————————————————————— - Treatment: - ARM A vs control (ARM B) 247 0.97 (0.66, 1.43) 0.8934 - Covariate: - Sex 247 0.1455 - F 0.77 (0.47, 1.27) - M 1.38 (0.75, 2.52) - Race 247 0.6850 - ASIAN 1.05 (0.63, 1.75) - BLACK OR AFRICAN AMERICAN 1.08 (0.51, 2.29) - WHITE 0.67 (0.27, 1.71) - Age 247 0.7878 - 34 0.95 (0.65, 1.40) + n Hazard Ratio 95% CI p-value Interaction p-value + ————————————————————————————————————————————————————————————————————————————————————————————————— + Treatment: + ARM A vs control (ARM B) 247 0.97 (0.66, 1.43) 0.8934 + Covariate: + Sex 247 0.1455 + F 0.77 (0.47, 1.27) + M 1.38 (0.75, 2.52) + Race 247 0.6850 + ASIAN 1.05 (0.63, 1.75) + BLACK OR AFRICAN AMERICAN 1.08 (0.51, 2.29) + WHITE 0.67 (0.27, 1.71) + Age 247 0.7878 + 34 0.95 (0.65, 1.40) # 3. Cox Regression (specifying covariates) Code res Output - n Hazard Ratio 95% CI p-value Interaction p-value - ——————————————————————————————————————————————————————————————————————————————————————————————————— - Treatment: - ARM A vs control (ARM B) 247 0.97 (0.66, 1.43) 0.8934 - Covariate: - Sex 247 0.1455 - F 0.77 (0.47, 1.27) - M 1.38 (0.75, 2.52) - Race 247 0.6850 - ASIAN 1.05 (0.63, 1.75) - BLACK OR AFRICAN AMERICAN 1.08 (0.51, 2.29) - WHITE 0.67 (0.27, 1.71) - Age 247 0.7878 - 30 0.98 (0.63, 1.51) - 40 0.91 (0.54, 1.51) - 50 0.84 (0.32, 2.20) + n Hazard Ratio 95% CI p-value Interaction p-value + ————————————————————————————————————————————————————————————————————————————————————————————————— + Treatment: + ARM A vs control (ARM B) 247 0.97 (0.66, 1.43) 0.8934 + Covariate: + Sex 247 0.1455 + F 0.77 (0.47, 1.27) + M 1.38 (0.75, 2.52) + Race 247 0.6850 + ASIAN 1.05 (0.63, 1.75) + BLACK OR AFRICAN AMERICAN 1.08 (0.51, 2.29) + WHITE 0.67 (0.27, 1.71) + Age 247 0.7878 + 30 0.98 (0.63, 1.51) + 40 0.91 (0.54, 1.51) + 50 0.84 (0.32, 2.20) # 4. Cox Regression (setting strata, ties, and alpha level) Code res Output - n Hazard Ratio 90% CI p-value Interaction p-value - ——————————————————————————————————————————————————————————————————————————————————————————————————— - Treatment: - ARM A vs control (ARM B) 247 0.97 (0.71, 1.34) 0.8934 - Covariate: - Sex 247 0.1455 - F 0.77 (0.47, 1.27) - M 1.38 (0.75, 2.52) - Race 247 0.6850 - ASIAN 1.05 (0.63, 1.75) - BLACK OR AFRICAN AMERICAN 1.08 (0.51, 2.29) - WHITE 0.67 (0.27, 1.71) - Age 247 0.7878 - 30 0.98 (0.68, 1.41) - 40 0.91 (0.59, 1.39) - 50 0.84 (0.38, 1.88) + n Hazard Ratio 90% CI p-value Interaction p-value + ————————————————————————————————————————————————————————————————————————————————————————————————— + Treatment: + ARM A vs control (ARM B) 247 0.97 (0.71, 1.34) 0.8934 + Covariate: + Sex 247 0.1455 + F 0.77 (0.47, 1.27) + M 1.38 (0.75, 2.52) + Race 247 0.6850 + ASIAN 1.05 (0.63, 1.75) + BLACK OR AFRICAN AMERICAN 1.08 (0.51, 2.29) + WHITE 0.67 (0.27, 1.71) + Age 247 0.7878 + 30 0.98 (0.68, 1.41) + 40 0.91 (0.59, 1.39) + 50 0.84 (0.38, 1.88) diff --git a/tests/testthat/_snaps/table_ratet01.md b/tests/testthat/_snaps/table_ratet01.md index 0b73ce09..e50dd889 100644 --- a/tests/testthat/_snaps/table_ratet01.md +++ b/tests/testthat/_snaps/table_ratet01.md @@ -3,26 +3,26 @@ Code res Output - B: Placebo A: Drug X C: Combination - (N=134) (N=134) (N=132) - —————————————————————————————————————————————————————————————————————————————————————————————————————— - Number of exacerbations per patient - 0 10 (7.46%) 6 (4.48%) 11 (8.33%) - 1 25 (18.66%) 21 (15.67%) 14 (10.61%) - 2 38 (28.36%) 41 (30.60%) 33 (25.00%) - 3 22 (16.42%) 26 (19.40%) 21 (15.91%) - 4 13 (9.70%) 18 (13.43%) 30 (22.73%) - 5 11 (8.21%) 10 (7.46%) 12 (9.09%) - 6 10 (7.46%) 7 (5.22%) 7 (5.30%) - 7 3 (2.24%) 4 (2.99%) 3 (2.27%) - 8 1 (0.75%) 1 (0.75%) 1 (0.76%) - 9 1 (0.75%) 0 (0.00%) 0 (0.00%) - Unadjusted exacerbation rate (per year) - Rate 7.2364 8.2148 9.8131 - Adjusted (QP) exacerbation rate (per year) - Rate 7.1215 8.2714 9.9508 - Rate CI (4.6899, 10.8140) (5.5080, 12.4212) (6.6579, 14.8723) - Rate Ratio 1.1615 1.3973 - Rate Ratio CI (0.6462, 2.0877) (0.7789, 2.5067) - p value 0.6169 0.2619 + B: Placebo A: Drug X C: Combination + (N=134) (N=134) (N=132) + ——————————————————————————————————————————————————————————————————————————————————————————————————— + Number of exacerbations per patient + 0 10 (7.46%) 6 (4.48%) 11 (8.33%) + 1 25 (18.66%) 21 (15.67%) 14 (10.61%) + 2 38 (28.36%) 41 (30.60%) 33 (25.00%) + 3 22 (16.42%) 26 (19.40%) 21 (15.91%) + 4 13 (9.70%) 18 (13.43%) 30 (22.73%) + 5 11 (8.21%) 10 (7.46%) 12 (9.09%) + 6 10 (7.46%) 7 (5.22%) 7 (5.30%) + 7 3 (2.24%) 4 (2.99%) 3 (2.27%) + 8 1 (0.75%) 1 (0.75%) 1 (0.76%) + 9 1 (0.75%) 0 (0.00%) 0 (0.00%) + Unadjusted exacerbation rate (per year) + Rate 7.2364 8.2148 9.8131 + Adjusted (QP) exacerbation rate (per year) + Rate 2.4550 2.8514 3.4304 + Rate CI (1.6194, 3.7219) (1.8974, 4.2850) (2.2946, 5.1284) + Rate Ratio 1.1615 1.3973 + Rate Ratio CI (0.6462, 2.0877) (0.7789, 2.5067) + p value 0.6169 0.2619 diff --git a/tests/testthat/test-pagination_listing.R b/tests/testthat/test-pagination_listing.R index eca6ab86..546e07ee 100644 --- a/tests/testthat/test-pagination_listing.R +++ b/tests/testthat/test-pagination_listing.R @@ -87,5 +87,9 @@ testthat::test_that("Direct pagination works fine", { pg_lst <- paginate_listing(lst_res, page_type = "a4", font_size = 9) testthat::expect_equal(length(pg_lst), 9L) - suppressWarnings(testthat::expect_warning(export_as_txt(lst_res, page_type = "a4", font_size = 9))) + testthat::expect_warning( # for footers \n + testthat::expect_error( # for internal \n + export_as_txt(lst_res, page_type = "a4", font_size = 9) + ) + ) }) diff --git a/tests/testthat/test-table_pkct01.R b/tests/testthat/test-table_pkct01.R index 8e3ac832..43d81f69 100644 --- a/tests/testthat/test-table_pkct01.R +++ b/tests/testthat/test-table_pkct01.R @@ -103,7 +103,7 @@ testthat::test_that("Specific PKCT01 features are present", { min = "Minimum", max = "Maximum" ), - na_level = "NE" + na_str = "NE" ) result <- build_table(lyt, df = adpc_1) %>% prune_table()